Business
Positive Results for NXP001 Clinical Trial
Positive Results for NXP001 Clinical Trial.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 5799A Nuformix PLC 30 May 2019 \n\n \nNuformix plc\n(\"Nuformix\" or the \"Company\")\n \nPositive Results for NXP001 Clinical Trial\n \nProprietary Cocrystal Technology Achieves Bioequivalence to Merck's EMEND®\n \nCambridge, UK, 30 May 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce positive results in its clinical study for the Company's lead programme NXP001.\n \nNXP001 is in development as a treatment for chemotherapy-induced nausea and vomiting (\"CINV\"), a large, under-exploited and growing market, which in demographic terms comprises one third of global cancer patients.\n \nIn a pilot study in healthy subjects, a proprietary cocrystal-based formulation developed within the NXP001 programme demonstrated bioequivalence to Merck's EMEND® at 125mg both in terms of peak exposure and overall exposure (Cmax and AUC).\n \nThe positive results from the trial now enable the Company to:\n \n· Confirm NXP001's potential for development as a treatment for CINV, enabling current and future licensees to launch new products into the £16bn oncology supportive care market\n· Trigger a final milestone payment of £2m from its Chinese licensing partner, Newsummit Biopharma, who have commenced product registration in China (Nuformix retains 10% royalty, with remaining milestone payments expected during June 2019)\n· Progress on-going discussions for licensing rest of world rights to NXP001 for CINV\n· Finalise further product development opportunities for the NXP001 programme to generate additional future value\n· Progress its wider portfolio using the Company's proven approach in identifying high-value applications for cocrystal technology\n \nDr Dan Gooding, CEO, Nuformix plc, said: \"We have now delivered a successful outcome in Nuformix's first clinical study. The results have positive implications for our NXP001 programme and provide further validation for Nuformix's overall business model. The results trigger payment of the final £2m milestone from Newsummit Biopharma, a...